Two Sigma Advisers LP Grows Stock Position in Encompass Health Co. (NYSE:EHC)

Two Sigma Advisers LP increased its holdings in Encompass Health Co. (NYSE:EHC) by 136.3% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 63,800 shares of the company’s stock after acquiring an additional 36,800 shares during the period. Two Sigma Advisers LP’s holdings in Encompass Health were worth $5,892,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. MassMutual Private Wealth & Trust FSB grew its holdings in shares of Encompass Health by 87.8% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company’s stock worth $27,000 after purchasing an additional 137 shares during the period. Colonial Trust Co SC purchased a new position in Encompass Health during the fourth quarter worth about $29,000. Transce3nd LLC acquired a new stake in shares of Encompass Health during the fourth quarter valued at about $40,000. CBIZ Investment Advisory Services LLC raised its stake in shares of Encompass Health by 38.7% in the 4th quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company’s stock valued at $42,000 after acquiring an additional 127 shares during the period. Finally, V Square Quantitative Management LLC lifted its holdings in shares of Encompass Health by 43.8% in the 4th quarter. V Square Quantitative Management LLC now owns 581 shares of the company’s stock worth $54,000 after acquiring an additional 177 shares during the last quarter. Institutional investors and hedge funds own 97.25% of the company’s stock.

Insider Transactions at Encompass Health

In related news, CEO Mark J. Tarr sold 118,384 shares of the business’s stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $121.53, for a total transaction of $14,387,207.52. Following the completion of the sale, the chief executive officer now owns 527,070 shares in the company, valued at $64,054,817.10. The trade was a 18.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Elissa Joy Charbonneau sold 4,279 shares of the company’s stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $116.61, for a total value of $498,974.19. Following the completion of the transaction, the insider now directly owns 11,958 shares of the company’s stock, valued at $1,394,422.38. This trade represents a 26.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 132,663 shares of company stock valued at $16,034,082. Insiders own 2.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. William Blair reissued an “outperform” rating on shares of Encompass Health in a research report on Friday, February 7th. Barclays boosted their price objective on Encompass Health from $118.00 to $129.00 and gave the company an “overweight” rating in a report on Friday, April 25th. UBS Group raised their target price on Encompass Health from $117.00 to $130.00 and gave the company a “buy” rating in a report on Monday, April 28th. KeyCorp boosted their price target on shares of Encompass Health from $120.00 to $122.00 and gave the stock an “overweight” rating in a research note on Friday, April 25th. Finally, Truist Financial reissued a “buy” rating and set a $135.00 price target (up previously from $116.00) on shares of Encompass Health in a research report on Monday, April 28th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $120.86.

Encompass Health Price Performance

Shares of NYSE EHC opened at $118.74 on Friday. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.05 and a quick ratio of 1.04. The company has a market cap of $11.97 billion, a price-to-earnings ratio of 26.62, a price-to-earnings-growth ratio of 2.31 and a beta of 0.91. The stock’s 50-day moving average is $107.85 and its two-hundred day moving average is $101.42. Encompass Health Co. has a 1-year low of $82.74 and a 1-year high of $121.96.

Encompass Health (NYSE:EHC) last released its earnings results on Thursday, April 24th. The company reported $1.37 earnings per share for the quarter, topping analysts’ consensus estimates of $1.19 by $0.18. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. The firm had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. During the same period in the prior year, the firm earned $1.12 earnings per share. The business’s quarterly revenue was up 10.6% compared to the same quarter last year. Analysts forecast that Encompass Health Co. will post 4.8 EPS for the current fiscal year.

Encompass Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Tuesday, July 1st will be issued a $0.17 dividend. The ex-dividend date of this dividend is Tuesday, July 1st. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.57%. Encompass Health’s payout ratio is 14.05%.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.